eligibility_summary
Eligible: age 6–29.99, Karnofsky/Lansky ≥60, confirmed CD30+ classical Hodgkin lymphoma, ASCT-eligible, disease is induction failure, progressive, or 1st–3rd relapse, confirmatory biopsy required, must meet ≥2 risk factors: performance <90, <1 year to first relapse, extranodal at relapse/progression, high MTV (>60 mL) on FDG PET/CT, chemo-resistant (Deauville 4–5) after first re-induction. Exclude: not meeting inclusion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b/II single-arm trial in poor-risk classical Hodgkin lymphoma testing autologous CD30-directed CAR T cells given 21–42 days after myeloablative BEAM conditioning and autologous stem cell transplant. Interventions: - CD30 CAR T cells (autologous, gene-modified cellular therapy), Phase 1b doses 1x10^8/m^2 or 2x10^8/m^2 to define RP2D. Mechanism: patient T cells engineered with a chimeric antigen receptor bind CD30 (TNFRSF8) on Hodgkin/Reed-Sternberg cells, activating CAR signaling (CD3ζ with co-stimulatory domains), leading to cytokine release and perforin/granzyme-mediated tumor lysis, TCR-independent recognition. Background therapy: BEAM myeloablative chemotherapy (cytotoxic DNA-damaging agents) for tumor debulking, followed by autologous stem cell rescue. Cells/pathways targeted: CD30+ malignant HRS cells, CAR signaling and downstream T-cell cytotoxic effector pathways.